MedTrace Logo

Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement

NCT04187014 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2021-04-28

No results posted yet for this study

Summary

This study compares two oral medications (tranexamic acid and aminocaproic acid) as hemostatic agent administered in patients undergoing primary total hip replacement

Conditions

  • Blood Loss, Surgical

Interventions

DRUG

Aminocaproic Acid 1000Mg Tab

Oral administration of a total 6 g of aminocaproic acid to reduce blood loss

DRUG

Tranexamic acid tablets

Oral administration of 3.9 g of tranexamic acid to reduce blood loss

Sponsors & Collaborators

  • Carlos A Acosta-Olivo

    lead OTHER

Principal Investigators

  • Carlos Acosta-Olivo, PhD · Universidad Autonoma de Nuevo Leon

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-06
Primary Completion
2021-04-26
Completion
2021-04-26

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04187014 on ClinicalTrials.gov